1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14670R
    Firocoxib (Standard) 189954-96-9
    Firocoxib (Standard) is the analytical standard of Firocoxib. This product is intended for research and analytical applications. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects.
    Firocoxib (Standard)
  • HY-146723
    IKKβ-IN-1 2410423-31-1 98%
    IKKβ-IN-1 is a potent and orally active IkappaB (IKK-β) inhibitor with IC50 of 0.20 μM. IKKβ-IN-1 can reduce PGE2 and TNF-α production in mouse macrophage cells. IKKβ-IN-1 has the ability to protect mice against septic shock induced mortality.
    IKKβ-IN-1
  • HY-146727
    JAK3-IN-11 2412734-00-8 98%
    JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases.
    JAK3-IN-11
  • HY-146729
    ASK1-IN-3 2426705-19-1 98%
    ASK1-IN-3 is a potent and selective ASK1 kinase inhibitor with IC50 of 33.8 nM, as well as inhibits several cell cycle regulating kinases. ASK1-IN-3 has strong HepG2 cancer cells apoptosis induction and potent cell cycle arrest activities.
    ASK1-IN-3
  • HY-146733
    PPARα agonist 1 3032632-02-0 98%
    PPARα agonist 1 is a potent and full hPPARα agonist.
    PPARα agonist 1
  • HY-146745
    Antileishmanial agent-5 2922333-29-5 98%
    Antileishmanial agent-4 is a ribonucleoside analogue and acts as an antileishmanial agent. Antileishmanial agent-4 is against L.infantum and T.cruzi with EC50 values of 0.68 μM and 0.83 μM, respectively.
    Antileishmanial agent-5
  • HY-146747
    Antifungal agent 26 2769834-78-6 98%
    Antifungal agent 26, a Pradimicin A derivative, shows antifungal, antiviral, and antiparasitic activities through binding to d-mannose (Man)-containing glycans of pathogenic species.
    Antifungal agent 26
  • HY-146757
    RIPK1-IN-13 1574547-67-3 98%
    RIPK1-IN-13 (Compound 8) is a potent inhibitor of RIPK1 with an IC50 value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases.
    RIPK1-IN-13
  • HY-146758
    RIPK1-IN-14 2919964-79-5 98%
    RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC50 value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells.
    RIPK1-IN-14
  • HY-146762
    MAO-B-IN-7 2851012-65-0 98%
    MAO-B-IN-7 is a potent and blood-brain barrier permeable MAO-B and AChE inhibitor with IC50s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage.
    MAO-B-IN-7
  • HY-146802
    NLRP3-IN-9 2768759-64-2 98%
    NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout.
    NLRP3-IN-9
  • HY-146974
    PDE4-IN-9 2519450-32-7 98%
    PDE4-IN-9 (Compound 5j) is a potent inhibitor of PDE4. PDE4-IN-9 exhibits lower IC50 value (1.4 μM) against PDE4 than parent rolipram (2.0 μM) in in vitro enzyme assay. PDE4-IN-9 also displays good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS.
    PDE4-IN-9
  • HY-146981
    α-Glucosidase-IN-3 2758286-48-3 98%
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivativ eagainst α-glucosidase(IC50=0.35 µM) and α-amylase.
    α-Glucosidase-IN-3
  • HY-146984
    α-Amylase-IN-2 2758286-53-0 98%
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
    α-Amylase-IN-2
  • HY-147085
    Loratadine n-oxide 165739-62-8 98%
    Loratadine n-oxide is a metabolite of Loratadine. Loratadine n-oxide shows antihistamine activity.
    Loratadine n-oxide
  • HY-147106
    Mrgx2 antagonist-1 2767110-35-8 98%
    Mrgx2 antagonist-1 (example 1) is a potent Mrgx2 (Mas-related Gene X2) antagonist. Mrgx2 antagonist-1 can be used for the research of MrgX2-mediated diseases and disorders.
    Mrgx2 antagonist-1
  • HY-147119
    INX-SM-6 2734878-16-9 98.85%
    INX-SM-6 can be used for targeted delivery of anti-inflammatory agent. INX-SM-6 inhibits LPS-induced IL-1β production in human PBMCS.
    INX-SM-6
  • HY-147195
    QH536 2754254-07-2 98%
    QH536 (Compound 29) is a potent HMGCR degrader with an EC50 of 0.22 μM. QH536 has no side-effect of inducing cholesterol accumulation in cells. QH536 shows anti-inflammatory and can be used for cardiovascular disease and nonalcoholic steatohepatitis research.
    QH536
  • HY-147234
    Sirtuin modulator 2 667910-69-2 99.22%
    Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM.
    Sirtuin modulator 2
  • HY-147247
    Fosimdesonide 98%
    Fosimdesonide, a small molecule of adalimumab fosimdesonide, is a potent immunomodulator. Fosimdesonide shows anti-inflammatory activity.
    Fosimdesonide
Cat. No. Product Name / Synonyms Application Reactivity